Rubius Therapeutics, Inc. - RUBY STOCK NEWS

Rubius Therapeutics (Nasdaq: RUBY) has appointed Noubar Afeyan, Ph.D., as chairman of its board, succeeding David Epstein, who remains a board member. Dr. Afeyan emphasizes the transformative potential of the company’s RED PLATFORM in developing cellular therapies for cancer and autoimmune diseases. Under the leadership of Pablo J. Cagnoni, the company plans to achieve several clinical milestones in the next year while building on its innovative foundation. The team established preclinical proof of concept for a type 1 diabetes treatment, showcasing the platform’s versatility and future therapeutic potential.

Rubius Therapeutics, Inc. (Nasdaq: RUBY) announced an update on its clinical trials, highlighting significant results from the Phase 1 arm of RTX-240, which demonstrated clinical responses and favorable tolerability in patients with advanced solid tumors. The company is expanding the RTX-240 trial to include patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Q1 2022 net loss was $52.4 million, reflecting increased R&D investments of $38.3 million compared to $27.7 million in Q1 2021. Cash reserves stand at $176.5 million, providing a runway into late 2023.

Rubius Therapeutics, Inc. (Nasdaq: RUBY) announced it will report its first quarter financial results on May 10, 2022, before market open. The company specializes in developing Red Cell Therapeutics™ for treating cancer and autoimmune diseases, leveraging its proprietary RED PLATFORM®. Notably, Rubius was recognized as one of the 2021 Top Places to Work in Massachusetts and its manufacturing site earned the 2021 Best Places to Work distinction in Rhode Island. No teleconference will accompany the financial results release.

Rubius Therapeutics (Nasdaq: RUBY) released updated clinical data from the ongoing Phase 1 trial of RTX-240, a cellular therapy for advanced solid tumors, at the American Association for Cancer Research Annual Meeting. The data, with a cutoff date of March 4, 2022, indicate that RTX-240 demonstrated disease control in 10 patients, including 3 with partial responses in non-small cell lung cancer, metastatic anal cancer, and metastatic uveal melanoma, without any treatment-related severe adverse events. The company plans to expand the trial to include combination therapy with pembrolizumab for further efficacy assessment.

Rubius Therapeutics (Nasdaq: RUBY) will hold a webcast on April 8, 2022, at 1:15 p.m. ET to discuss updated clinical data from its Phase 1 arm of the RTX-240 trial. This clinical trial focuses on patients with advanced solid tumors and relapsed/refractory acute myeloid leukemia. Dr. Alexander I. Spira, a noted investigator, will also participate to discuss future opportunities in oncology therapeutics. Investors can access the webcast through the company's website or by phone. This highlights Rubius's ongoing commitment to developing innovative cellular medicines.

Rubius Therapeutics has announced it will present updated results from its Phase 1 clinical trial of RTX-240 in advanced solid tumors at the AACR Annual Meeting on April 12, 2022. The company will also host an investor webcast on April 8, 2022, to discuss these results and next steps for Phase 2 clinical development. Initial results reported in March 2021 indicated clinical proof of concept for RTX-240 in treating advanced solid tumors. The ongoing study aims to assess safety, tolerability, and anti-tumor activity of RTX-240.

Rubius Therapeutics (NASDAQ: RUBY) announced its fourth quarter and full year 2021 financial results, reporting a net loss of $55 million for Q4 and $196.5 million for the year. R&D expenses rose to $141.6 million, reflecting investment in clinical trials for RTX-240 and RTX-321. The company continues significant advancements in its oncology pipeline, with several clinical data milestones expected in 2022, including results from its RTX-240 trials and the initiation of RTX-240 Phase 2 expansion cohorts. As of end-2021, Rubius holds $225.8 million in cash, providing a runway into mid-2023.

Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its fourth quarter and full year 2021 financial results on February 25, 2022, before market open. The company specializes in Red Cell Therapeutics™, focusing on developing innovative cellular medicines for cancer and autoimmune diseases. Importantly, it will not hold a teleconference to discuss the results. Recently, Rubius was recognized as one of the Top Places to Work in Massachusetts and its manufacturing site received accolades in Rhode Island.

Rubius Therapeutics (Nasdaq: RUBY) has announced its participation in two significant investor events during February 2022. CEO Pablo J. Cagnoni will present a corporate update at the Guggenheim Healthcare Talks on February 10 at 8:00 a.m. EST and at the SVB Leerink Global Healthcare Conference on February 18 at 1:00 p.m. EST. These sessions will focus on the company's innovative approach to developing Red Cell Therapeutics™ for treating cancer and autoimmune diseases. Live webcasts of the presentations will be available, with archived replays for 90 days.